New drug combo shows promise for Hard-to-Treat blood cancer
NCT ID NCT02537613
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This phase 1 study tests a combination of two drugs, ibrutinib and obinutuzumab, in 54 people with chronic lymphocytic leukemia (CLL) that has returned or not responded to prior treatment. The main goal is to check safety and find the best dosing schedule. Researchers will also look at how well the combination shrinks or controls the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University of Rochester Wilmot Cancer Inst.
Rochester, New York, 14642, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ibrutinib and obinutuzumab
What this could lead to
If it works, this could offer a new treatment option for people with CLL that has come back or not responded to other therapies.
What could go wrong
This is a small, early-phase trial focused on safety, not proof of effectiveness. The combination may cause side effects and may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.